4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.88 Average Price Target from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $30.6667.

Several brokerages have recently issued reports on FDMT. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. B. Riley Financial initiated coverage on 4D Molecular Therapeutics in a report on Friday, July 31st. They issued a “buy” rating and a $37.00 target price for the company. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. The Goldman Sachs Group set a $33.00 price objective on 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $10.28 on Thursday. The stock has a 50-day simple moving average of $10.67 and a 200 day simple moving average of $9.71. 4D Molecular Therapeutics has a 52 week low of $5.33 and a 52 week high of $14.00. The stock has a market capitalization of $537.40 million, a P/E ratio of -4.00 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. Research analysts forecast that 4D Molecular Therapeutics will post -3.88 earnings per share for the current year.

Insider Activity

In related news, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider owned 8,617 shares in the company, valued at $103,404. The trade was a 53.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Kirn sold 12,415 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total transaction of $124,770.75. Following the transaction, the insider directly owned 871,737 shares in the company, valued at approximately $8,760,956.85. This represents a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 197,226 shares of company stock worth $2,200,677. 7.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Exome Asset Management LLC bought a new stake in 4D Molecular Therapeutics during the 1st quarter valued at $1,216,000. Evergreen Quality Fund GP Ltd. purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth approximately $7,136,000. Simplify Asset Management Inc. purchased a new position in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $656,000. Baker BROS. Advisors LP purchased a new stake in 4D Molecular Therapeutics in the 4th quarter valued at $3,568,000. Finally, Janus Henderson Group PLC grew its stake in shares of 4D Molecular Therapeutics by 13.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after acquiring an additional 611,276 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.